sample photo

The GSK Immunotherapeutics (ITx) Business Unit is at the forefront of unlocking the potential ability of the immune system to attack diseases, from cancer to conditions such as diabetes, in early stages. ITx therapies stimulate a new or increased immune response that stops disease progression - and possibly even prevents disease onset - holding promising potential for developing ‘game-changing’ treatments.


Turnstone helped to build the ITx business plan and developed several online and offline communications as well as business presentations to share the ongoing developments of the business plan with the different ITx teams and GSK management.

Our services for this client